Gu Yuting, Zhang Jing, Guan Huai
Department of Gynaecology and Obstetrics, Daqing Longnan Hospital, Daqing, Heilongjiang 163000, P.R. China.
Oncol Lett. 2017 Dec;14(6):7191-7196. doi: 10.3892/ol.2017.7171. Epub 2017 Oct 11.
Expression of enhancer of zeste homolog 2 (EZH2) has been implicated in cancer pathology, but research on its mechanistic activity is limited. The present study sought to assess the levels expression of EZH2 in patients with endometrial carcinoma (EC) and to explore the effects of EZH2 downregulation on the biological behavior of endometrial carcinoma RL-952 cells. Samples were obtained from a total of 104 patients with EC and an immunohistochemical assay was used to detect the expression of EZH2 in cancer and adjacent tissues. The relationship between the expression of EZH2 and the clinicopathological features was analyzed. Endometrial carcinoma RL-952 cells were transfected with chemically synthesized siRNA to conduct targeting inhibition of EZH2 expression. The expression levels of EZH2 protein were detected by immunoblotting. MTT and Transwell assays were used to detect the changes of cell proliferation and invasion after EZH2 downregulation. Of the 104 cases of endometrial carcinoma samples, 71 cases showed positive expression of EZH2, with an expression rate of 68.27%. In 104 cases of adjacent tissue samples, 25 cases showed positive expression of EZH2, with an expression rate of 24.03%. The expression of EZH2 in endometrial carcinoma tissue was significantly higher than that in adjacent tissue (P<0.05). The expression of EZH2 in endometrial carcinoma tissue was not correlated with the menopausal status and age of patients (P>0.05), but was correlated with the histological grade, depth of tumor invasion, lymph node metastasis and TNM stage (P<0.05). The expression of E2H2 was significantly downregulated by si-E2H2 and the proliferation and invasion abilities of cells were significantly reduced after EZH2 downregulation (P<0.05). EZH2 is closely related to the development of endometrial carcinoma and can enhance the proliferative activity of endometrial carcinoma RL-952 cells and promote cell invasion.
zeste同源物2增强子（EZH2）的表达与癌症病理学有关，但其机制活性的研究有限。本研究旨在评估子宫内膜癌（EC）患者中EZH2的表达水平，并探讨EZH2下调对子宫内膜癌RL-952细胞生物学行为的影响。共收集104例EC患者的样本，采用免疫组织化学法检测癌组织及癌旁组织中EZH2的表达。分析EZH2表达与临床病理特征之间的关系。用化学合成的小干扰RNA转染子宫内膜癌RL-952细胞，对EZH2表达进行靶向抑制。通过免疫印迹法检测EZH2蛋白的表达水平。采用MTT法和Transwell法检测EZH2下调后细胞增殖和侵袭能力的变化。104例子宫内膜癌样本中，71例EZH2呈阳性表达，表达率为68.27%。104例癌旁组织样本中，25例EZH2呈阳性表达，表达率为24.03%。子宫内膜癌组织中EZH2的表达明显高于癌旁组织（P<0.05）。子宫内膜癌组织中EZH2的表达与患者的绝经状态和年龄无关（P>0.05），但与组织学分级、肿瘤浸润深度、淋巴结转移及TNM分期有关（P<0.05）。si-E2H2可显著下调E2H2的表达，EZH2下调后细胞的增殖和侵袭能力明显降低（P<0.05）。EZH2与子宫内膜癌的发生密切相关，可增强子宫内膜癌RL-952细胞的增殖活性并促进细胞侵袭。
